Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Core Viewpoint - Outlook Therapeutics has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) [2][4] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for retinal diseases, including wet AMD [4] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for wet AMD treatment [4] - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and UK in the second quarter of 2025 [4] Clinical Development - In the United States, ONS-5010 / LYTENAVA™ is currently investigational and is undergoing a non-inferiority study for wet AMD treatment [4] - Successful results from the study may allow the company to resubmit a Biologics License Application (BLA) to the FDA [4] - If approved, ONS-5010 / LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for retinal indications in the U.S. [4] Investor Engagement - The company participated in the Virtual Investor "Top 5 for '25" On-Demand Conference, where the CFO and Interim CEO presented key reasons for investor interest in Outlook Therapeutics [3]